DFE Pharma has announced the launch of its new Continuous Manufacturing (CM) platform in collaboration with Gericke.
In a release, the company said the new CM platform is designed to support pharmaceutical companies in formulation development, optimisation and lifecycle management of CM processes.
The new initiative integrates ready-to-use excipients, a flexible evaluation environment and multidisciplinary expertise, enabling data-driven decisions from early exploration through to optimisation and long-term operation.
Collaboration with Gericke
As part of the CM platform, DFE Pharma has invested in continuous manufacturing capability at its C2F Center of Excellence in Hyderabad, India, featuring a Gericke Formulation Skid (GFS).
This advanced formulation skid features modular feeding and blending options and is located in a non-GMP environment.
This setup allows for rapid iterations and practical assessment and optimisation without disrupting existing GMP manufacturing or requiring upfront infrastructure investment.
The modular setup at the C2F Center facilitates flexible process and formulation testing by integrating the GFS with pre-blending, as well as downstream processing and analytical capabilities, to provide decision-relevant insights.
This equipment allows pharmaceutical companies to experience the practical operation of continuous feeding and blending, test formulation strategies using CM-ready materials and understand how evaluation data translates directly into real-world implementation.
Why this matters
Continuous manufacturing is a process in which raw materials are continuously fed, transformed through controlled operations and discharged as finished products.
This is a small extract of the full article which is available
ONLY to premium content subscribers.
Click below to get premium content on Manufacturing Chemist.
Not yet a Subscriber?